Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease

Anesthesia and Analgesia

Volumn 111, Issue 1, 2010, Pages 185-190

  Vukcevic, Mirko ^a   Broman, Marcus ^b   Islander, Gunilla ^b   Bodelsson, Mikael ^b   Ranklev Twetman, Eva ^b   Müller, Clemens R ^c   Treves, Susan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; RYANODINE RECEPTOR 1; THAPSIGARGIN; 4 CHLORO 2 CRESOL; 4-CHLORO-2-CRESOL; CALCIUM; CRESOL; DIAGNOSTIC AGENT; DNA; MESSENGER RNA; RYANODINE RECEPTOR;

ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CALCIUM CONDUCTANCE; CALCIUM TRANSPORT; CENTRAL CORE DISEASE; CLINICAL ARTICLE; DNA EXTRACTION; DOSE RESPONSE; ENVIRONMENTAL TEMPERATURE; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MALIGNANT HYPERTHERMIA; PRIORITY JOURNAL; RNA EXTRACTION; SWEDEN; ADULT; BIOPSY; BIOSYNTHESIS; BLOOD; CELL LINE; DRUG EFFECT; FEMALE; GENETICS; HETEROZYGOTE; MALE; METABOLISM; METHODOLOGY; MUSCLE CONTRACTION; MUTATION; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; SKELETAL MUSCLE;

ADULT; BIOPSY; BLOOD SPECIMEN COLLECTION; CALCIUM; CELL LINE; CHILD, PRESCHOOL; CRESOLS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC TESTING; HETEROZYGOTE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUTATION; MYOPATHY, CENTRAL CORE; RNA, MESSENGER; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SWEDEN;

EID: 77954684290     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181cbd815     Document Type: Article

References (30)

1. Hopkins PM. Malignant hyperthermia. Advances in clinical management and diagnosis. Br J Anaesth 2000;85:118-28
2. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stiegliz M, Tegazzin V, Urwuyler A, Wappler F. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group: results of testing patients surviving fulminant MH and unrelated lowrisk subjects. The European Malignant Hyperthermia group. Acta Anaesthesiol Scand 1997;41:955-66
3. Quinlivan RM, Müller C, Davis M, Laing NG, Evans GA, Dove J, Roberts AP, Sewry CA. Central core disease: clinical, pathological, and genetic features. Arch Dis Child 2003;88:1051-5
4. Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008;8:319-26
5. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-89
6. Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S, Zorzato F. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscul Disord 2005;15:577-87
7. Carafoli E. Intracellular calcium homeostasis. Ann Rev Biochem 1987;56:395-433
8. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signaling. Nat Rev Mol Cell Biol 2000;1:11-21
9. Berridge M, Bootman MD, Roderick HL. Calcium signaling: dynamics, homeostasis and remodeling. Nat Rev Mol Cell Biol 2003;4:817-21
10. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 2006;33:715-31
11. Divet A, Paesante S, Bleuven C, Anderson A, Treves S, Zorzato F. Novel sarco (endo) plasmic reticulum proteins and calcium homeostasis in striated muscles. J Muscle Res Cell Motil 2005;26:7-12
12. Protasi F, Franzini-Armstrong C, Allen PD. Role of ryanodine receptors in the assembly of calcium release units in skeletal muscle. J Cell Biol 1998;140:831-42
13. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Romero N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J. Correlations between genotype and pharmacological, histological, functional and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005;26:413-25
14. Sei Y, Gallagher KL, Basile AS. Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem 1999;274:5995-6002
15. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwuyler A, Zorzato F, Treves S. B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001;276:48077-82
16. Broman M, Gehrig A, Bodelsson M, Ranklev-Twetman E, Ruffert H, Müller C. Mutation screening of the RYR1-cDNA from peripheral B lymphocytes in 15 Swedish malignant hyperthermia index cases. Br J Anaesth 2009;102:642-9
17. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis R, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-9
18. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Müller CR, Treves S. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001;10:2879-87
19. McKinney LC, Butler T, Mullen SP, Klein MG. Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia. Anesthesiology 2006;104:1191-1201
20. 2+]. Anesthesiology 2000;92:1799-1806
21. 2+]. Am J Physiol Cell Physiol 2005;288:606-12
22. Wu S, Ibarra MC, Mclicdan MC, Murayama K, Ichihara Y, Kikuchi H, Nonaka I, Noguchi S, Hayashi YK, Nishino I. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006;129:1470-80
23. Driessen J. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist? Curr Opin Anaesthesiol 2008;21:350-5
24. Ducreaux S, Zorzato F, Müller CR, Sewry C, Muntoni F, Quinlivan R, Restagno G, Girard T, Treves S. Effect of ryanodine receptor mutations on IL-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia susceptible individuals and patients affected by central core disease. J Biol Chem 2004;279:43838-46
25. Ducreux S, Zorzato F, Ferreiro A, Jungbluth H, Muntoni F, Monnier N, Müller CR, Treves S. Functional properties of ryanodine receptors carrying 3 amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalised lymphocytes. Biochem J 2006;395:259-66
26. Anderson AA, Brown RL, Polster B, Pollock N, Stowell KM. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology 2008;108:208-15
27. Lyfenko AD, Ducreux S, Wang Y, Xu L, Zorzato F, Ferreiro A, Meissner G, Treves S, Dirksen RT. Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle EC coupling by distinct mechanisms. Hum Mutat 2007;28:61-8
28. Levano S, Vukcevic M, Singer M, Matter A, Treves S, Urwuyler A, Girard T. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009;30:590-8
29. Weiss R, O'Connell K, Flucher B, Allen P, Grabner M, Dirksen R. Functional analysis of the R1068H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004;287:1094-102
30. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001;86:283-7